导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.85% | 3579/4773 |
| 近一周 | -2.30% | 3701/5465 |
| 近一月 | 1.02% | 370/5421 |
| 近一季 | 1.22% | 756/5231 |
| 近半年 | -5.73% | 3078/4920 |
| 近一年 | -4.07% | 3134/4394 |
| 近两年 | 22.78% | 2591/2954 |
| 近三年 | 12.46% | 1696/2253 |
| 成立以来 | 222.89% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.36% 3818/4961 |
-8.34% 3874/5312 |
- - |
- - |
| 2025 | 8.14% 2909/4813 |
-1.41% 2660/3635 |
3.57% 989/4076 |
1.78% 3869/4524 |
4.05% 578/4813 |
| 2024 | 23.26% 343/3463 |
4.53% 450/2808 |
4.40% 216/3014 |
15.46% 1710/3129 |
-2.18% 1988/3463 |
| 2023 | -8.71% 1049/2656 |
2.43% 1351/2280 |
-0.53% 388/2385 |
-1.79% 582/2515 |
-8.76% 2307/2655 |
| 2022 | -10.74% 216/2207 |
-6.96% 233/1919 |
2.83% 1253/2016 |
-11.06% 488/2113 |
4.90% 505/2208 |
| 2021 | 3.73% 603/1822 |
2.01% 234/1255 |
0.79% 1082/1330 |
-1.72% 538/1466 |
2.65% 546/1822 |
| 2020 | 25.51% 618/1250 |
-10.57% 793/1028 |
8.41% 823/1067 |
16.82% 130/1164 |
10.82% 578/1184 |
| 2019 | 37.81% 329/1092 |
24.18% 524/754 |
2.14% 96/804 |
1.17% 425/850 |
7.40% 439/918 |
| 2018 | -16.87% 115/834 |
- - |
- - |
- - |
-12.16% 415/691 |
| 2017 | 28.54% 76/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.75% 165/605 |
- - |
- - |
- - |
- - |
| 2015 | 2.32% 239/575 |
- - |
- - |
- - |
- - |
| 2014 | 64.70% 22/237 |
- - |
- - |
- - |
- - |
| 2013 | -8.03% 134/186 |
- - |
- - |
- - |
- - |
| 2012 | 15.10% 13/140 |
- - |
- - |
- - |
- - |
| 2011 | -18.30% 23/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信责任ETF VS. 长安沪深300非周期A(740101) |